The first batch of the new, highly-targeted, khatna vaccination regimen has hit the market.
The vaccine has been approved by the U.S. Food and Drug Administration (FDA) and has been tested on animals at the FDA’s Center for Food Safety and Applied Nutrition, which has also been involved in testing vaccines for the first time in humans.
A preliminary safety test results show the vaccine has a 99% efficacy rate and is safe for humans.
The FDA is recommending that people who have had khatnas or who have been in contact with an infected person take two doses.
The company, Khatnas Pharmaceuticals, has said the vaccine is also being used in the treatment of viral diseases, which include Lyme disease, and is not currently licensed for use in humans because it hasn’t been proven safe.
The vaccines have been approved for use by the FDA for three years.
The first dose, the Khatnas V1.0, is expected to be administered to people between the ages of 18 and 35 in the U:A second dose of the vaccine, Kshatriya V1, will be given to people over the age of 60 in the first half of 2019.
In the meantime, KSHTR Pharma has developed a new khatnastick vaccine that will be administered by mouth to people who are in close contact with someone who has been infected with the coronavirus, including people who live in rural areas.
Kshatriyan, the new vaccine, is based on the company’s khatniastick, a synthetic form of the natural Khatnian tree.
The new vaccine contains an active ingredient called the Kshatnani tree resin, which is made from the leaves of the khatnian plant.KSHTR Pharmaceuticals is expected by the company to release the kshatriyas V2.0 vaccine later this year.
The first batch is expected be available for $300 per dose, while the second batch will cost $400 per dose.
The company will also release a Khatnaras V3.0 supplement containing a khatnicene-based extract that will cost between $600 and $1,200 per dose per person.